Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Phase II study to evaluate safety of Azacitidine PLUS Durvalumab (medi4736) in MDS/AML
Clinical Trial Grant
Duke Scholars
Principal Investigator
Carlos Manuel de Castro III
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
Celgene Corporation
Start Date
November 17, 2016
End Date
March 9, 2021
Awarded By
Celgene Corporation
Start Date
November 17, 2016
End Date
March 9, 2021
